Trial Profile
A Combined Phase 1 and Phase 2 Study of Albumin-bound Rapamycin Nanoparticles (Nab-rapamycin, ABI-009) in the Treatment of BCG Refractory or Recurrent Nonmuscle Invasive Transitional Cell Bladder Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 22 May 2022
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors AADi
- 07 Dec 2019 Status changed from recruiting to completed.
- 18 Jul 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.
- 10 May 2016 Results of phase I study (n=13) presented at the 111th Annual Meeting of the American Urological Association.